Swiss National Bank grew its stake in Core Laboratories N.V. (NYSE:CLB) by 0.3% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 161,300 shares of the oil and gas company’s stock after buying an additional 500 shares during the period. Swiss National Bank owned approximately 365,345.41% of Core Laboratories N.V. worth $15,920,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the business. Principal Financial Group Inc. purchased a new stake in shares of Core Laboratories N.V. in the 3rd quarter valued at $17,950,000. Oregon Public Employees Retirement Fund boosted its stake in shares of Core Laboratories N.V. by 248.5% in the 3rd quarter. Oregon Public Employees Retirement Fund now owns 22,765 shares of the oil and gas company’s stock valued at $2,247,000 after purchasing an additional 16,233 shares in the last quarter. Prudential Financial Inc. purchased a new stake in shares of Core Laboratories N.V. in the 3rd quarter valued at $2,560,000. State of Wisconsin Investment Board boosted its stake in shares of Core Laboratories N.V. by 2.3% in the 3rd quarter. State of Wisconsin Investment Board now owns 86,218 shares of the oil and gas company’s stock valued at $8,510,000 after purchasing an additional 1,898 shares in the last quarter. Finally, Stevens Capital Management LP purchased a new stake in shares of Core Laboratories N.V. in the 3rd quarter valued at $1,944,000.

Core Laboratories N.V. (NYSE:CLB) opened at $100.51 on Monday. The company has a debt-to-equity ratio of 1.53, a current ratio of 2.18 and a quick ratio of 1.81. Core Laboratories N.V. has a 1-year low of $86.55 and a 1-year high of $125.83. The company has a market cap of $4,437.25, a price-to-earnings ratio of 54.92 and a beta of 1.57.

Core Laboratories N.V. (NYSE:CLB) last issued its quarterly earnings data on Monday, October 23rd. The oil and gas company reported $0.48 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.04. Core Laboratories N.V. had a net margin of 12.06% and a return on equity of 52.89%. The business had revenue of $166.20 million during the quarter, compared to analyst estimates of $160.94 million. During the same period in the prior year, the business earned $0.38 EPS. The company’s revenue for the quarter was up 1.4% on a year-over-year basis. sell-side analysts predict that Core Laboratories N.V. will post 1.99 earnings per share for the current fiscal year.

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, November 21st. Investors of record on Friday, October 20th will be paid a $0.55 dividend. The ex-dividend date of this dividend is Thursday, October 19th. This represents a $2.20 annualized dividend and a dividend yield of 2.19%. Core Laboratories N.V.’s payout ratio is 126.44%.

ILLEGAL ACTIVITY WARNING: This report was first reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/11/20/swiss-national-bank-grows-holdings-in-core-laboratories-n-v-clb.html.

CLB has been the subject of a number of research reports. Deutsche Bank AG initiated coverage on shares of Core Laboratories N.V. in a research note on Tuesday, October 10th. They issued a “buy” rating and a $109.00 price objective for the company. Zacks Investment Research cut shares of Core Laboratories N.V. from a “hold” rating to a “sell” rating in a research report on Tuesday, October 17th. Scotiabank set a $136.00 price target on shares of Core Laboratories N.V. and gave the company a “hold” rating in a research report on Wednesday, October 25th. Royal Bank Of Canada dropped their price target on shares of Core Laboratories N.V. from $115.00 to $112.00 and set an “outperform” rating for the company in a research report on Thursday, September 7th. Finally, ValuEngine cut shares of Core Laboratories N.V. from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Four analysts have rated the stock with a sell rating, seven have given a hold rating and six have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average price target of $108.64.

About Core Laboratories N.V.

Core Laboratories N.V. provides reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company operates through three segments: Reservoir Description, Production Enhancement and Reservoir Management. The Reservoir Description segment encompasses the characterization of petroleum reservoir rock, fluid and gas samples.

Institutional Ownership by Quarter for Core Laboratories N.V. (NYSE:CLB)

Receive News & Stock Ratings for Core Laboratories N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Core Laboratories N.V. and related stocks with our FREE daily email newsletter.